Studi relawan sehat di Mesquite, TX
7 studi di lokasi sekitar Mesquite menerima relawan sehat — orang tanpa kondisi yang sedang diteliti. Banyak studi membayar peserta atas waktu dan perjalanan mereka; jumlah pembayaran ditentukan oleh masing-masing studi, jadi tanyakan kepada tim studi.
Teks studi resmi (Bahasa Inggris)
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Menerima pesertaSukarelawan sehat diterima
- SMS Clinical Research, Mesquite
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
Menerima pesertaFase 3Sukarelawan sehat diterima
- SMS Clinical Research LLC, Mesquite
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
Menerima pesertaFase 3Sukarelawan sehat diterima
- GSK Investigational Site, Mesquite
This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- VAST Clinical Research, Mesquite
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
Menerima pesertaFase 3Sukarelawan sehat diterima
- SMS Clinical Research LLC, Mesquite
- SMS Clinical Research LLC, Mesquite
- SMS Clinical Research LLC., Forney · 8 mi jauhnya
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Menerima pesertaFase 3Sukarelawan sehat diterima
- GSK Investigational Site, Mesquite
A Study to Learn About mRNA Vaccines Against Influenza in Adults
Menerima pesertaFase 2Sukarelawan sehat diterima
- SMS Clinical Research LLC, Mesquite
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.